[{"arm_notes": "", "treatment_id": null, "treatment_name": "TODO PreventionIntervention group: Participants in the 12-17 years age group will receive two intramuscular doses of 10\u03bcg/200\u03bcl vaccine strengths on days 0 and 21, followed by an intranasal dose on day 51. Participants in the 5-11 years age group will receive half the dose of 12-17 years old's with the same administration schedule.", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]

[{"arm_notes": "", "treatment_id": 1066, "treatment_name": "Razi cov pars", "treatment_type": "Protein subunit", "pharmacological_treatment": "Vaccine"}]

[{"arm_notes": "", "treatment_id": null, "treatment_name": "TODO PreventionIntervention group: Participants in this group will receive two doses (IM) of RAZI recombinant spike protein vaccine 21 days apart followed by a nasal spray 51 days after the first dose (day 0).", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]

[{"arm_notes": "", "treatment_id": 1066, "treatment_name": "Razi cov pars", "treatment_type": "Protein subunit", "pharmacological_treatment": "Vaccine"}]